CLINICAL TRIAL: RALTEGRAVIR (MK-0518), ON THE LEVEL OF PERSISTENT PLASMA VIREMIA

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Purpose: To find out if adding raltegravir reduces the amount of HIV in the blood using a test that measures very low amounts of the virus. Participants: 50 HIV-1 infected men and women. Procedures (methods): A5244 is double-blind, randomized, placebo-controlled study. At study entry the subjects will be randomized to one of the following arms: Arm A (immediate intensification) or Arm B (delayed intensification).